All In Biotech

Drug Trial Radar · NCT03459222

An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread

A Phase 1/2 Study of Relatlimab (Anti-LAG-3 Monoclonal Antibody) Administered in Combination With Both Nivolumab (Anti-PD-1 Monoclonal Antibody) and BMS-986205 (IDO1 Inhibitor) or in Combination With Both Nivolumab and Ipilimumab (Anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors

Last checked: Nov 19, 2026Latest source record: Apr 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

229

Actual

Start

May 30, 2018

Primary completion

Feb 19, 2025

Study completion Feb 19, 2025

Sponsor

Lead sponsor
Bristol-Myers SquibbBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Mar 8, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to demonstrate the safety and preliminary activity with triple combinations of relatlimab in combination with nivolumab and BMS-986205, or in combination with nivolumab and ipilimumab in immunotherapy-naive and pretreated populations across select advanced tumor types.

Conditions

  • Advanced Cancer

Interventions

  • RelatlimabBiological

    Specified dose on specified days

  • NivolumabBiological

    Specified dose on specified days

  • BMS-986205Drug

    Specified dose on specified days

  • IpilimumabBiological

    Specified dose on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Grade 3/Grade 4 Laboratory Test ResultsTime frame: From first dose (Day 1) and within 30 days of last dose of study therapy (up to approximately 69 months)
  2. Number of Participants With Adverse Events and DeathsTime frame: From first dose (Day 1) and within 30 days of last dose of study therapy (up to approximately 69 months)
  3. Number of Participants With Dose Limiting ToxicitiesTime frame: From first dose (Day 1) and up to 42 days post first dose
  4. Objective Response Rate (ORR)Time frame: From the date of first dose (Day 1) to up to the date of objectively documented progression or the date of subsequent anti-cancer therapy, whichever occurs first (up to 80 months)
  5. Disease Control Rate (DCR)Time frame: From the date of first dose (Day 1) to up to the date of objectively documented progression or the date of subsequent anti-cancer therapy, whichever occurs first (up to 80 months)
  6. Duration of Response (DoR)Time frame: From the date of first dose (Day 1) to up to the date of objectively documented progression or the date of subsequent anti-cancer therapy, whichever occurs first (up to 80 months)

Locations

22 sites in 7 countries. Site status is shown where the registry gives one.

  • Local Institution - 0006

    Duarte, California

  • Local Institution - 0003

    Aurora, Colorado

  • Local Institution - 0004

    Baltimore, Maryland

  • Local Institution - 0005

    St Louis, Missouri

  • Local Institution - 0001

    Germantown, Tennessee

  • Local Institution - 0012

    Wollstonecraft, New South Wales, Australia

  • Local Institution - 0011

    Nedlands, Western Australia, Australia

  • Local Institution - 0017

    Marseille, France

  • Local Institution - 0016

    Toulouse, France

  • Local Institution - 0015

    Villejuif, France

  • Local Institution - 0010

    Forlì, Italy

  • Local Institution - 0009

    Naples, Italy

  • Local Institution - 0023

    Rome, Italy

  • Local Institution - 0019

    Barcelona, Spain

  • Local Institution - 0021

    Madrid, Spain

  • Local Institution - 0018

    Madrid, Spain

  • Local Institution - 0022

    Málaga, Spain

  • Local Institution - 0020

    Pamplona, Spain

  • Local Institution - 0008

    Lausanne, Switzerland

  • Local Institution - 0007

    Zurich, Switzerland

  • Local Institution - 0013

    Headington, United Kingdom

  • Local Institution - 0014

    Newcastle upon Tyne, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.